Citation Impact
Citing Papers
A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
2012
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
2009 Standout
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
1998
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data
1997 Standout
Primary thromboprophylaxis for cancer patients with central venous catheters – a reappraisal of the evidence
2006
Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-inducible Factor 1
1996 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
The relationship between prognostic and predictive factors in the management of breast cancer
1998
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Venous Thromboembolism and Cancer: Prevention of VTE
2001
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
2009
The risk of venous thromboembolism is increased throughout the course of malignant glioma
2000
Suppression of tumor growth through disruption of hypoxia-inducible transcription
2000 StandoutNobel
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
2006
Measuring Quality of Life in Asthma
1993
Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.
1996
Long-term results of the co-operative German–Austrian–Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs
1998
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Hepatitis C Virus Infection
2001 Standout
The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trials
2007
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
1993
International Collaboration is Feasible in Trials for Rare Conditions: The EURAMOS Experience
2009
Assessing the quality of life—a study in newly-diagnosed breast cancer patients
1990
Assessing quality of life in head and neck cancer
1992
Metabolism and action of amino acid analog anti-cancer agents
1990
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
2009 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Assessment of Quality-of-Life Outcomes
1996 Standout
Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
1998
The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome
1995 Standout
Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial
2000
A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma
2008 Standout
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
1993
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup
1997
Two-Stage Revision for Infected Endoprostheses Used in Tumor Surgery
2002
Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials
1995
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Platelet Activation and Atherothrombosis
2007 Standout
Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas
1988
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Chemotherapy for Osteosarcoma without High-Dose Methotrexate: A 12-Year Follow-Up on 53 Patients
2007
Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation.
1995
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
2009
Tumor size and prognosis in aggressively treated osteosarcoma.
1996
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
1990
Chemotherapy Is Associated With Improved Survival in Adult Patients With Primary Extremity Synovial Sarcoma
2007
A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer
2000
Bone tumours in European children and adolescents, 1978–1997. Report from the Automated Childhood Cancer Information System project
2006
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Prevention of Venous Thromboembolism
2004 Standout
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.
1997 Standout
The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study.
1996
Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute
2001
Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study
1997
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
2001 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Head and Neck Cancer
1993 Standout
Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution
2004
Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials
1992
Prevention of Venous Thromboembolism
2008 Standout
Delaying surgery with chemotherapy for osteosarcoma of the extremities
2004
Adjuvant Epirubicin With or Without Ifosfamide for Adult Soft-Tissue Sarcoma
2002
Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study
2005
Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup
2007
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
1993 Standout
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Quantifying heterogeneity in a meta‐analysis
2002 Standout
Hemorrhagic Complications of Anticoagulant Treatment
2001 Standout
Treatment of Infections Associated with Surgical Implants
2004 Standout
Analysis of the factors influencing the quality of life of patients with advanced or recurrent breast cancer
1995
Hemorrhagic Complications of Anticoagulant Treatment
2004
Venous thromboembolism and survival in patients with high-grade glioma
2007
Management of Anticoagulation before and after Elective Surgery
1997
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
Common Musculoskeletal Tumors of Childhood and Adolescence
1999
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
2001
Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer
2009
Upper Extremity Deep Venous Thrombosis in Cancer Patients with Venous Access Devices - Prophylaxis with a Low Molecular Weight Heparin (Fragmin)
1996
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Minidose Warfarin and Failure to Prevent Deep Vein Thrombosis After Joint Replacement Surgery Despite Inhibiting the Postoperative Rise in Plasminogen Activator Inhibitor Activity
1995
Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer
2006
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
1992
A randomized trial for the treatment of high-grade soft-tissue sarcomas of the extremities: preliminary observations.
1986
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
Systems to rate the strength of scientific evidence.
2002
Clinical Trials on Antiphospholipid Syndrome: What is Being Done and What is Needed?
1994
State-of the-Art Review : Prevention of Thrombosis in Gynecologic Malignancy
1998
Venous Thromboembolism and Cancer: Risks and Outcomes
2003
Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial
2005
Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma.
1996 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102
2005
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
2002 Standout
Effects of Fixed Low-Dose Warfarin, Aspirin-Warfarin Combination Therapy, and Dose-Adjusted Warfarin on Thrombogenesis in Chronic Atrial Fibrillation
2000
Using Single-Agent Therapy in Adult Patients with Advanced Soft Tissue Sarcoma Can Still Be Considered Standard Care
2005
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
2001
Delay in Diagnosis of High-Grade Osteosarcoma of the Extremities. Has it any Effect on the Stage of Disease?
2000
Adjuvant Chemotherapy for Soft Tissue Sarcomas
1991
Metabolic reprogramming and cancer progression
2020 StandoutScience
A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'-d(GAC).
1995 StandoutNobel
Adjuvant Therapy Of Soft-Tissue Sarcomas
1995
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
1997 StandoutNobel
The treatment of soft tissue sarcomas with focus on chemotherapy: A review
1986
Adjuvant Chemotherapy for Adult Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial
2001
Adjuvant Chemotherapy for Soft Tissue Sarcomas
1995
Development and validation of a predictive model for chemotherapy-associated thrombosis
2008 Standout
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
2015 Standout
Enzymatic aminoacylation of tRNA with unnatural amino acids
2006 StandoutNobel
Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)
2004
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Metabolism of oxazaphosphorines
1988
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients
2005
Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5
2005
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis
2002
Thromboembolism in Hospitalized Neutropenic Cancer Patients
2006
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
2002 Standout
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
2012
Minidose Warfarin Prophylaxis for Catheter-Associated Thrombosis in Cancer Patients: Can It Be Safely Associated With Fluorouracil-Based Chemotherapy?
2003
Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651
2003
Works of V. Bramwell being referenced
The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma.
1997
Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
1994
A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma
2001
A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup.
1992
Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
1994
A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial
2006
Grading of soft tissue sarcomas: Experience of the EORTC soft tissue and bone sarcoma group
1993
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
1998
A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12)
2009
Quality of life in stage II breast cancer: an instrument for clinical trials.
1988
Do authors of review articles use systematic methods to identify, assess and synthesize information?
1997
Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.
1993
Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma group
1984
Adjuvant Treatment of Soft Tissue Sarcoma in Children and Adults
1979
N-(Phosphonacetyl)-l-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group
1982
Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5)
2006
Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505
2008
Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2
1992
STEROID-HORMONE RECEPTORS AND SURVIVAL AFTER FIRST RELAPSE IN BREAST CANCER
1984
Chemotherapy for metastatic soft tissue sarcomas – another full circle?
1991
Concentrations of N-(Phosphonacetyl)-l-aspartate (PALA) in plasma and tears in man
1981
Repeated investigations of cyclophosphamide disposition in myeloma patients receiving intermittent chemotherapy.
1980